Publication | Closed Access

Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study

Breast OncologyBreast Cancer PatientsMedicineClinical TrialsMultiple CyclesBreast CancerCancer TreatmentOncologyPhase Iii Study